Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i&gt;-rearranged acute lymphoblastic leukemia. Haematologica 2023;108(2):457-471; https://doi.org/10.3324/haematol.2022.281456.